|
307 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...8182838485868788899091...9899» |
- | Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine (clinicaltrials.gov) - Jul 23, 2012
P4, N=37, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed
- |||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: Long-term Study With Clevudine (clinicaltrials.gov) - Jul 23, 2012
P4, N=150, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients (clinicaltrials.gov) - Jul 23, 2012
P4, N=100, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection (clinicaltrials.gov) - Jul 23, 2012
P3, N=92, Completed, Sponsor: Bukwang Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| GSK 2336805 / J&J
New P2 trial, Combination therapy: Dose Ranging of GSK2336805 in Combination Therapy (clinicaltrials.gov) - Jul 22, 2012
P2, N=115, Active, not recruiting, Sponsor: GlaxoSmithKline
- Enrollment closed: The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: University of Cincinnati
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion: Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy (clinicaltrials.gov) - Jul 19, 2012
P2, N=107, Completed, Sponsor: ArQule
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | New P2 trial: A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection (clinicaltrials.gov) - Jul 18, 2012
P2, N=114, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- ||||| tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue (clinicaltrials.gov) - Jul 18, 2012
P3, N=166, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2/3 trial: BOS3: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jul 18, 2012
P2/3, N=240, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- miravirsen (SPC3649) / BMS, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial: Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects (clinicaltrials.gov) - Jul 18, 2012
P1, N=5, Completed, Sponsor: Santaris Pharma A/S
- | Trial completion, Monotherapy: A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers (clinicaltrials.gov) - Jul 18, 2012
P1, N=18, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Enrollment change: Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure (clinicaltrials.gov) - Jul 17, 2012
P3, N=200, Recruiting, Sponsor: Vital Therapies, Inc.
Active, not recruiting --> Completed N=152 --> 200
- Clinical: Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI) (clinicaltrials.gov) - Jul 17, 2012
P=N/A, N=75, Not yet recruiting, Sponsor: VA Connecticut Healthcare System
- | New P2 trial: Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=135, Recruiting, Sponsor: National Cancer Center, Korea
- |||| Ganovo (danoprevir) / Roche, Ascletis, Pfizer, Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection (clinicaltrials.gov) - Jul 16, 2012
P2, N=229, Completed, Sponsor: Hoffmann-La Roche
N=152 --> 200 Active, not recruiting --> Completed
- Surgery: Laparoscopic Versus Open Surgery for the Management of Cystic Echinococcosis of the Liver (clinicaltrials.gov) - Jul 15, 2012
P=N/A, N=350, Completed, Sponsor: Medical Park Gaziantep Hospital
- |||||||||| ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) (clinicaltrials.gov) - Jul 15, 2012
P3, N=1400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Victrelis (boceprevir) / Roche, Merck (MSD)
New P3 trial, Combination therapy: Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) (clinicaltrials.gov) - Jul 15, 2012
P3, N=0, Withdrawn, Sponsor: Merck
- |||||||||| Pegasys (pegylated interferon ? -2a) / Roche
New P3 trial: NEUTRINO: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (clinicaltrials.gov) - Jul 15, 2012
P3, N=328, Completed, Sponsor: Gilead Sciences
- ||| Xalkori (crizotinib) / Pfizer
Enrollment open, Metastases: Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients (clinicaltrials.gov) - Jul 15, 2012
P1, N=70, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Reasanz (serelaxin) / Novartis
New P2 trial: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - Jul 12, 2012
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- Trial completion: Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jul 12, 2012
P=N/A, N=56, Completed, Sponsor: San Antonio Military Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- 5-fluorouracil / Generic mfg.
Trial termination, Surgery: Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer (clinicaltrials.gov) - Jul 12, 2012
P2, N=0, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- entecavir / Generic mfg.
New P1 trial: Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients (clinicaltrials.gov) - Jul 12, 2012
P1, N=9, Completed, Sponsor: Genexine, Inc.
- ||||| New P4 trial: Hepatic Xenetix-CT Perfusion (clinicaltrials.gov) - Jul 11, 2012
P4, N=78, Active, not recruiting, Sponsor: Guerbet
- |||| Enrollment open, Preclinical: Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis (clinicaltrials.gov) - Jul 11, 2012
P2, N=60, Recruiting, Sponsor: Stempeutics Research Pvt Ltd
Active, not recruiting --> Terminated; low accrual Not yet recruiting --> Recruiting
- || New P3 trial: CaSSY: Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms (clinicaltrials.gov) - Jul 11, 2012
P3, N=256, Active, not recruiting, Sponsor: University of Pittsburgh
- JNJ-47910382 / J&J
Enrollment open: A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients (clinicaltrials.gov) - Jul 11, 2012
P1, N=18, Recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || sorafenib / Generic mfg.
Enrollment change: GIDEON: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (clinicaltrials.gov) - Jul 10, 2012
P=N/A, N=3721, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting N=3000 --> 3721
- | entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial, Monotherapy: IN-US-0205: Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B (clinicaltrials.gov) - Jul 10, 2012
P4, N=102, Active, not recruiting, Sponsor: Asan Medical Center
- Signifor LAR (pasireotide long acting release) / Recordati
New P2 trial: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 10, 2012
P2, N=30, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- ||| sorafenib / Generic mfg.
Trial completion: GIDEON: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (clinicaltrials.gov) - Jul 10, 2012
P=N/A, N=3721, Completed, Sponsor: Bayer
N=3000 --> 3721 Active, not recruiting --> Completed
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion: Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jul 10, 2012
P1, N=21, Completed, Sponsor: ArQule
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tyzeka (telbivudine) / Novartis
Enrollment change, Monotherapy: Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB) (clinicaltrials.gov) - Jul 9, 2012
P2, N=15, Completed, Sponsor: The University of Hong Kong
Active, not recruiting --> Completed N=60 --> 15
- | Tyzeka (telbivudine) / Novartis
Trial completion, Monotherapy: Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB) (clinicaltrials.gov) - Jul 9, 2012
P2, N=15, Completed, Sponsor: The University of Hong Kong
N=60 --> 15 Not yet recruiting --> Completed
- faldaprevir (BI201335) / Boehringer Ingelheim
New P1 trial: Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone (clinicaltrials.gov) - Jul 9, 2012
P1, N=34, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Hepatocellular Carcinoma (HCC)_Torisel_ (clinicaltrials.gov) - Jul 9, 2012
P1/2, N=50, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=370, Active, not recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting N=200 --> 370
- | Promacta (eltrombopag) / Novartis
New P2 trial: Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients (clinicaltrials.gov) - Jul 8, 2012
P2, N=45, Active, not recruiting, Sponsor: GlaxoSmithKline
- Enrollment closed: Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=370, Active, not recruiting, Sponsor: University of British Columbia
N=200 --> 370 Recruiting --> Active, not recruiting
- omega-3 ethylester concentrate / Generic mfg.
Trial termination: Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jul 4, 2012
P2, N=12, Terminated, Sponsor: University of Illinois at Chicago
Recruiting --> Active, not recruiting Enrolling by invitation --> Terminated; Terminated due to low enrollment.
- | Pegasys (pegylated interferon α -2a) / Roche
Enrollment change, Combination therapy: A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. (clinicaltrials.gov) - Jul 4, 2012
P3, N=50, Active, not recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Terminated; Terminated due to low enrollment. N=37 --> 50
- || Pegasys (pegylated interferon α -2a) / Roche
Enrollment closed: An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=1849, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=37 --> 50 Recruiting --> Active, not recruiting
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change, Monotherapy: A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies (clinicaltrials.gov) - Jul 4, 2012
P1, N=29, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=24 --> 29
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change: A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both (clinicaltrials.gov) - Jul 4, 2012
P1, N=30, Completed, Sponsor: Hoffmann-La Roche
N=24 --> 29 N=25 --> 30
- ||| Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B (clinicaltrials.gov) - Jul 4, 2012
P4, N=200, Completed, Sponsor: Hoffmann-La Roche
N=25 --> 30 N=134 --> 200
- | tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs (clinicaltrials.gov) - Jul 4, 2012
P3, N=32, Active, not recruiting, Sponsor: GlaxoSmithKline
N=134 --> 200 Recruiting --> Active, not recruiting
- ||| IDX 184 / Merck (MSD)
Enrollment closed, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Jul 4, 2012
P2, N=60, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jul 2, 2012
P2, N=58, Completed, Sponsor: University of Nottingham
Recruiting --> Active, not recruiting Recruiting --> Completed